Melissa B, Epperly's Net Worth
$9.63 Million
Who is Melissa B, Epperly?
Melissa B, Epperly has an estimated net worth of $9.63 Million. This is based on reported shares across multiple companies, which include Zentalis Pharmaceuticals, Inc., Nautilus Biotechnology, Inc., Kinnate Biopharma Inc., and Roivant Sciences Ltd..
SEC CIK
Melissa B, Epperly's CIK is 0001807359
Past Insider Trading and Trends
2023 was Melissa B, Epperly's most active year for acquiring shares with 8 total transactions. Melissa B, Epperly's most active month to acquire stocks was the month of January. 2021 was Melissa B, Epperly's most active year for disposing of shares, totalling 22 transactions. Melissa B, Epperly's most active month to dispose stocks was the month of November. 2021 saw Melissa B, Epperly paying a total of $499,748.14 for 89,861 shares, this is the most they've acquired in one year. In 2021 Melissa B, Epperly cashed out on 52,685 shares for a total of $2,800,554.74, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Zentalis Pharmaceuticals, Inc. (ZNTL) Snapshot price: $11.34
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -0.57% | -2.57K |
$11.44 | -$29,435.12 | 451.45K |
Feb 12
| |||
Form 4
| +17.11% | 66.33K |
$11.54 | -$100,040.26 | 454.02K |
Feb 1 - Feb 2
| |||
Form 4
| -1.39% | -5.48K |
$19.50 | -$106,925.60 | 387.69K |
Oct 4
| |||
Form 4
| -1.96% | -7.85K |
$20.13 | -$158,004.52 | 392.05K |
Scheduled
|
Feb 13 - Feb 14
| ||
Form 4
| +34.22% | 101.96K |
—
|
—
| 399.9K |
Feb 1
| |||
Form 4
| +20.20% | 50K |
—
|
—
| 297.54K |
Oct 3
| |||
Form 4
| -6.46% | -17.08K |
$50.09 | -$855,522.43 | 247.41K |
Scheduled
|
Apr 4
| ||
Form 4
| -0.72% | -1.91K |
$49.10 | -$93,920.75 | 264.49K |
Scheduled
|
Feb 23
| ||
Form 4
| +6.56% | 16.41K |
—
|
—
| 266.41K |
Feb 10
| |||
Form 4
| -6.40% | -17.08K |
$67.13 | -$1,146,580.40 | 250K |
Oct 2
| |||
Form 4
| +3.74% | 9.61K |
$52.00 | $499,748.14 | 266.69K |
Aug 18 - Aug 19
| |||
Form 4
| -1.19% | -3.08K |
$51.27 | -$158,054.33 | 257.07K |
Scheduled
|
Jul 1
| ||
Form 4
| -1.17% | -3.08K |
$54.05 | -$166,640.95 | 260.16K |
Scheduled
|
Jun 1
| ||
Form 4
| -1.16% | -3.08K |
$59.24 | -$182,634.73 | 263.24K |
Scheduled
|
May 3
| ||
Form 4
| -6.04% | -17.11K |
$43.39 | -$742,323.38 | 266.32K |
Scheduled
|
Apr 5
| ||
Form 4
| -1.08% | -3.08K |
$41.67 | -$128,482.48 | 283.43K |
Scheduled
|
Mar 1
| ||
Form 4
| +5.52% | 15K |
—
|
—
| 286.51K |
Feb 11
| |||
Form 4
| -1.12% | -3.08K |
$37.56 | -$115,804.67 | 271.51K |
Scheduled
|
Feb 1
| ||
Form 4
| -1.11% | -3.08K |
$51.91 | -$160,033.81 | 274.6K |
Scheduled
|
Jan 4
| ||
Form 4
| -4.70% | -13.68K |
$52.18 | -$714,059.90 | 277.68K |
Scheduled
|
Dec 4 - Dec 7
| ||
Form 4
| -1.05% | -3.08K |
$51.47 | -$158,680.78 | 291.36K |
Scheduled
|
Dec 2
| ||
Form 4
| +6.10% | 16.92K |
$32.29 | $216,386.49 | 294.45K |
Scheduled
|
Apr 7 - Nov 23
| ||
Form 4
| +113.26% | 147.39K |
—
|
—
| 277.53K |
Apr 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Nautilus Biotechnology, Inc. (NAUT) Snapshot price: $2.72
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Kinnate Biopharma Inc. (KNTE) Snapshot price: $2.35
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Roivant Sciences Ltd. (ROIV) Snapshot price: $10.395
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +4.75% | 1.02K |
$10.90 | -$1,340.70 | 22.56K |
Apr 24
| |||
Form 4
| +5.94% | 1.21K |
—
|
—
| 21.54K |
Jan 19
| |||
Form 4
| +6.42% | 1.23K |
—
|
—
| 20.33K |
Oct 16
| |||
Form 4
| +1,392.58% | 17.82K |
—
|
—
| 19.11K |
Sep 12
| |||
Form 4
|
∞
| 1.28K |
—
|
—
| 1.28K |
Jul 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||